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Abstract
It is widely accepted that neuroblastoma origin from Neural Crest Cells (NCC). NCC is a 
group of embryonic cells located in proximity to neural tube. During the embryonic devel-
opment they migrate to generate the ganglia of sympathetic nervous system and the adre-
nal medulla. More than 50% of neuroblastoma masses are detected in the abdomen but the 
phases of tumorigenesis during the embryonic life are still unknown. Neuroblastoma cells 
show numerous copy number aberrations (CNAs), both numerical and structural. Several 
non-random CNAs are detected in clinical stage 4 and associated with tumor aggres-
siveness. On the contrary, neuroblastoma cells of infants or young patients have several 
numerical CNAs that are associated with a favorable outcome. MYCN oncogene ampli-
fication was one of the first genetic abnormalities observed in neuroblastoma and was 
found correlated to tumor aggressiveness. About 1% of all neuroblastoma show a heredi-
table fashion. Nowadays, the ALK gene has been discovered as predisposition gene for 
neuroblastoma. Moreover, thank to the genome-wide association studies, BARD1, LMO1 
and LIN28 genes have been found linked to neuroblastoma predisposition. The two-step 
and multistep models are not satisfied the genesis of this tumor making the study of neu-
roblastoma tumorigenesis mandatory. Recently, the role of chromosome instability (CIN) 
became prominent to explain the neuroblastoma development. Indeed, the chromothrip-
sis was observed in neuroblastoma cells of clinical stage 4, supporting the high genomic 
instability of these cells. The role of CIN in neuroblastoma is still unclear, but several 
experimental data suggest that CIN has a pivotal part in the genesis of neuroblastoma.
Keywords: neuroblastoma, neural crest cells, tumorigenesis, chromosomal instability, 
two-hit model, multistep model, chromosome instability
1. Introduction
The OMICs (the OMICs is a neologism referred to the study of: genomics, proteomics, tran-
scriptomics, etc.) study of neuroblastoma has produced a huge amount of data generated by 
© 2017 The Author(s). Licensee InTech. This chapt r is distributed under the terms of the Creative Comm s
Attribution L cense (http://creativecommons. /licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
genomics profiling, gene expression and epigenetics analysis [1]. Nevertheless, these studies 
supply information about the picture of primary tumors or metastatic cells only at onset of the 
disease. More recently, Schramm et al. [2] were able to study the genome of neuroblastoma 
comparing the mutational profiling of tumor cells at onset of disease and at time of patient’s 
relapse. This allowed the authors to investigate the tumor clonal evolution and demonstrate 
that new mutations were acquired during the tumor progression. Recurrent mutations in tumor 
of relapsed patients included: cadherin 5 (CDH5), dedicator of cytokinesis 8 (DOCK8), protein-
tyrosine phosphatase nonreceptor type 4 (PTPN14), Harvey rat sarcoma viral oncogene homolog 
(HRAS) and Kirsten rat sarcoma viral oncogene homolog (KRAS), providing a lot of information 
concerning new mutations present in the tumor of patient at relapse. Since patient’s relapse is a 
critical step in the cure of neuroblastoma for the reason that, usually, tumor is not responding to 
the therapy, it is reasonable that new mutations contribute to increase tumor aggressiveness and 
drug resistance. MYCN oncogene amplification is one of the most important gene abnormalities 
found in neuroblastoma, and it is largely used as tumor unfavorable marker. The MYCN status 
(normal versus amplified) is used to classify the relapse patient’s risk. Consequently, in the last 
decade, in order to perform precision medicine, particular attention was focused to find muta-
tions candidate to drug targeting [3].
However, although the OMICs approach allowed us to identify some new drugs useful for tar-
get therapy, the cure of neuroblastoma is partially ineffective with a 5‐year overall survival of 
35% [4].
Actually, the overall OMICs studies are lacking important information about the origin of 
neuroblastoma. Really, we do not know how and when the mutations that we observed 
are occurring in neuroblastoma cells. Some animal models have been produced to reca-
pitulate the growth and development of neuroblastoma, and some mathematical models 
have been generated to mimic the tumorigenesis of the tumor, but the overall informa-
tion about the genesis of neuroblastoma is still missing. Certainly, the deep knowledge 
about the neuroblastoma tumorigenesis will greatly contribute to the cure of this pediatric 
cancer.
2. From neural crest cell to neuroblastoma cell
There are evidences that neuroblastoma tumor cells originate from neural crest cell (NCC) 
[5, 6]. Most of neuroblastoma cells produce homovanillic acid and vanillylmandelic acid, two 
metabolites involved in catecholamine synthesis of sympathetic nervous system [7, 8].
The neuroblastoma is comprised in Neuroblastic Tumors a group of tumors with great 
heterogeneous morphology [9]. Neuroblastoma cells show small cell body with few cyto-
plasm and abundant nucleus, while some neuritis protrudes by the cell body. Neuroblastic 
Tumors are classified as: Neuroblastoma Schwannian stroma‐poor (undifferentiated, poorly 
differentiated, differentiating), Ganglioneuroblastoma intermixed Schwannian stroma‐rich 
and Ganglioneuroma. Undifferentiated Neuroblastoma Schwannian stroma‐poor is one of the 
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most aggressive Neuroblastic Tumors, whereas Ganglioneuroblastoma intermixed Schwan‐
nian stroma‐rich and Ganglioneuroma are less aggressive. Ganglioneuroblastoma and Gang‐
lioneuroma display heterogeneous morphology with large cells resembling ganglionic-like 
cells or Schwann‐like cells. The latter are also identified as stromal cells. In Figure 1, the cell 
morphology of some Neuroblastic Tumors is shown.
It is also interesting to report that neuroblastoma cells of human-established cell lines produce a 
lot of long neuritis, creating a dense neural network after all-trans retinoid acid (ATRA) treatment 
[10, 11]. Moreover, the treatment with ATRA blocks the cellular proliferation inducing neuroblas-
toma cellular maturation. More than 50% of the patients onset with an abdominal mass, while 
other patients have head, neck and paraspinal infiltrated lymph‐nodes [7]. Trunk NCC moves 
from dorsal to ventral region to form sympathetic ganglia and adrenal medulla.
It is still unclear if these cells are also a committee to become malignant neuroblastoma cells 
or if the malignant transformation is initiated after the NCC reached their final destination.
Figure 1. Morphological heterogeneity of neuroblastic tumors. (A) Poorly differentiated neuroblastoma stroma‐poor 
(magnification 20x) and (B) same tumor (magnification 40x). Tumor tissue shows small blue cells with few cytoplasm and 
few stroma. (C) Ganglioneuroblastoma intermixed Schwannian stroma‐rich (magnification 20x). Cells are embedded in 
abundant stroma. (D) Ganglioneuroma, very benign tumor; most of the tissue is stroma, and some ganglionic‐like cells 
are visible (yellow arrow) (kindly provided by Dr. Luisa Santoro, University of Padua, Italy).
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There are several evidences that neuroblastoma arises during fetal life. Ikeda et al. [12] 
have observed neuroblastoma cells in autoptic samples of infants. This observation clearly 
indicates that tumor may grow and develops during the fetal life. Patients with neuroblas-
toma stage 4S, a special group of patients that develop the tumor within one year of age 
and that may show onset of disease in the first month of life (Figure 2), are presumably 
developing the tumor already before birth. This has been demonstrated by Gigliotti et al. 
[13] who reported that six cases out of 45 stage 4S neuroblastomas were detected in utero. 
So that, we have several, indicating that neuroblastoma tumorigenesis may initiate during 
the fetal life.
3. Familial neuroblastoma and predisposition to neuroblastoma
About 1% of all neuroblastoma show familial cases. Genetic screenings of several families with 
recurrent neuroblastoma have shown that tumor is transmitted as recessive trait at low pene-
trance. In 2007, Longo et al. [14] have demonstrated a significant likelihood ratio for locus 2p by 
linkage analysis. Further, Mosse et al. [15] identified a locus at the chromosome region 2p23‐24 
with 104 genes that also included the MYCN gene. Next analysis showed significant mutations of 
Anaplastic Lymphoma Kinase (ALK) gene associated with the neuroblastoma predisposition. In 
neuroblastoma, ALK gene synthetizes the tyrosine alk receptor. Receptor autophosphorylation is 
promoted by mutation in kinase domain, and it is activating the alk pathway. Both germline and 
somatic ALK mutations were observed in neuroblastoma. Up to now, several mutations have been 
found in the kinase domain, but the most frequents are R1275 (43%), F1174 (30%) and F1245 (12%).
Figure 2. Distribution of stage 4S and stage 4 patients at onset during the first year of life. Most of stage 4S patients (red 
column) onset between 0 and 8 months, whereas patients at stage 4 (blue column) onset more frequently after 5 months [14].
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It is interesting to note that in human, both MYCN [16] and ALK [17] genes are highly 
expressed during the embryonic life and their expression decreases after the born. MYCN 
and ALK expression is not appreciable in the tissues of adult.
Recently, genome‐wide association studies (GWAS) have been used to identify susceptibility 
gene variants in neuroblastoma. The GWAS studies are very useful to associate gene polymor-
phisms to tumor predisposition. Bosse et al. [18] identified the BARD1 β, an isoform of BARD1 
gene, associated with high‐risk neuroblastoma. Oldridge et al. [19] found a polymorphism at 
locus of LMO1 gene significantly associated with neuroblastoma susceptibility. In particular, 
they found the SNP rs 2168101, the variant most highly associated with the disease. A further 
association was found for LIN28B variants, making the LIN28B gene significantly involved in 
the neuroblastoma susceptibility [20].
4. Genomics and transcriptomics abnormalities in neuroblastoma cell
DNA content in neuroblastoma cells shows great variability. Most of the tumors with favorable 
evolution show triploid or near-triploid cells, whereas tumor of patients with unfavorable out-
come shows diploid, near-diploid or tetraploid cells. Tumor of favorable cases has whole addi-
tional chromosomes and few structural damages, whereas tumor of patients with poor outcome 
usually has several nonrandom structural changes and few numerical chromosome aberrations 
[21–23].
Studies of neuroblastoma cell genome, by microarray comparative genomic hybridization, 
have shown the following nonrandom structural copy number aberrations (CNAs): deletions 
of chromosomes 1p36 region, 3p, 4p, 9p 11q 14q together gain of 1q, 2p24, 12p, 17q [21, 22, 24]. 
Structural CNAs are more frequently observed in tumor of patients with aggressive metastatic 
disease, and indeed, structural chromosome abnormalities are significantly associated with 
high tumor aggressiveness and disease progression [25]. This picture indicates that neuroblas-
toma cells have high chromosomal instability. Gain of chromosome 2p region is mainly due to 
the amplification of MYCN gene. The amplification of MYCN gene was discovered in 1984 and 
is the most robust genomic abnormality observed in about 20% of neuroblastoma [26]. Gene 
copies can range from four to over 1000, and MYCN gene amplification is significantly associ-
ated with rapid tumor growth and disease progression [27].
As well as CNAs, the gene expression of neuroblastoma cells was investigated by microarray 
technology. Gene expression profiling was found significantly different between localized 
and metastatic tumors. Oberthuer et al. [28, 29] have identified a 144‐gene signature associ-
ated with tumor aggressiveness and poor patients’ outcome. Moreover, a 59-gene signature 
has been also found associated with patient’s risk although neither 144‐ nor 59‐gene signa-
tures are currently used as prognostic markers [30]. Recently, we have looked for the global 
gene expression between localized and metastatic tumors. This difference was calculated for 
each gene and called as transcription instability (TIN), and we generated a TIN-index that is 
significantly higher in metastatic tumor in respect of the localized one. Our study shows that 
gene expression is highly deregulated in advanced tumors [submitted manuscript].
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5. One, two, multistep: the tumorigenesis of neuroblastoma
The tumorigenesis of neuroblastoma is still unclear. Neuroblastoma shows a great biologi-
cal and genetics heterogeneity, suggesting that more than one gene is involved in the tumor 
initiation and progression. Neuroblastoma stroma-poor shows great potential of growth 
and rapidly forms metastases distally from primary tumor, indicating that gene mutations 
increase the tumor cell invasion capacity. On the contrary, ganglioneuroblastoma has low 
aggressiveness, indicating that not all gene mutations are critical for tumor growth and inva-
sion. Ganglioneuroblastoma is composed by malignant neuroblasts and Schwannian stromal 
cells; the latter, possibly, are playing a tumor suppression activity by regulating the tumor 
microenvironment. Indeed, several observations report a complex cross-talk between neuro-
blastoma cells and Schwannian stroma cells, manly mediated by cytokines [31, 32]. Lastly, 
neuroblastoma cells of clinical stage 4S still are a fascinating problem, because this metastatic 
tumor can regress spontaneously. To explain disease regression of stage 4S tumor, it has 
been proposed that neuroblastoma cells are delayed to achieve the complete cell differentia-
tion before the birth of patient, but the cell maturation is completed within the first year of 
patient’s age [33].
Knudson and Meadows [34] have suggested the presence of a recessive NB gene to explain 
the behavior of stage 4S tumor, a model resembling the recessive RB gene discovered in reti-
noblastoma. Since chromosome 1p36 region has been found deleted in more than 40% of 
cases, this region was a candidate locus to contain NB‐suppressor gene [35]. Indeed, if one NB 
gene would be located in the deleted chromosome 1p36 region, the two-hit model should be 
fit in the carcinogenesis of neuroblastoma. Unfortunately, linkage analysis of neuroblastoma 
pedigrees has not revealed NB‐genes in the 1p36 region.
Recently, animal models that recapitulate the genesis of neuroblastoma are produced in mouse 
and in zebrafish. MYCN human oncogene has been overexpressed in transgenic mouse, dem-
onstrating that tumor growth is under MYCN control. Similarly, neuroblastoma can grow 
in mouse overexpressing ALK or LIN28. In zebrafish model, the overexpression of MYCN 
gene blocks the development of sympathoadrenal precursor toward the chromaffin‐like cells, 
inducing the formation of neuroblastoma cells in the interrenal gland. Neuroblastoma tumor 
growing in both mouse and zebrafish resembles human neuroblastoma in many of aspects 
such as cell morphology [36]. Zebrafish has been also employed to study the embryonic devel-
opment of NCC. These cells can be easily identified by the expression of SOX10 (Sry-box 10) 
and Crestin genes that are expressed in migratory NCC. So, the precise and detailed analysis 
of NCC development during physiological embryonic life of zebrafish can greatly help to 
generate new models for the study of neuroblastoma tumorigenesis.
Finally, since several chromosome regions are affected in neuroblastoma tumor, it is reason-
able to think that numerous genes are impaired giving a sort of multifactorial or multistep 
damage to the normal cells [37]. Loss of chromosome 1p36 region, 3p, 4p, 9p 11q 14q together 
gain of 1q, 2p24, 12p, 17q, mutations of ALK and receptor tyrosine kinase (AXL) gene, and 
telomerase reverse transcriptase (TERT) re-arrangements may be seen as mutational steps, 
leading to the transformation of normal neural crest cell to neuroblastoma cell.
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In this contest, the role of gene mutation seems not sufficient to transform the normal cell into 
neuroblastoma, at least for all Neuroblastic Tumors because the frequency of gene mutation in 
neuroblastoma, as well as other pediatric cancer, is dramatically lower than mutations observed 
in adult cancer. On the other hand, few genes can have critical damaging mutations that are 
dangerous for the pathways in which genes work, suggesting an oligogenic mechanism of neu-
roblastoma tumorigenesis [38].
6. Chromosome instability and neuroblastoma
The low number of mutations in neuroblastoma suggests that abnormalities in gene sequenc-
ing play a role in some but not in all neuroblastoma. The more aggressive tumors are belong-
ing to patients over one year of age with metastatic disease; these patients with stage 4 
disease have a median age of onset between four and five years. Differently from infants’ 
patients, tumor cells of stage 4 patients over one year of age have several nonrandom struc-
tural CNAs. Others and we have suggested that tumor cells of these patients accumulate 
chromosome damages in a time‐dependent manner [39, 40]. As consequence, this suggests 
a multistep manner of neuroblastoma development and it is reasonable to think that several 
alterations such as single gene mutation, gene deletion, gene amplification, gene rearrange-
ment, and gross chromosome aberrations participate in the neuroblastoma tumorigenesis. 
This hypothesis is also supported by the discovery of chromothripsis, a catastrophic defect 
mainly occurring in chromosome 5 that damages almost all chromosome regions [41]. More 
recently, I suggested that chromosomal instability (CIN) plays a crucial role in the neuro-
blastoma development [42]. CIN is a feature of most cancers and can be caused by abnormal 
mitosis, failure in the microtubule and centrosome dynamics, or spindle apparatus, abnormal 
control of double-strand break repair, telomere maintenance, and abnormal telomere func-
tion. Several genes are involved in the mentioned mechanisms, and so they can be considered 
CIN-related genes. Carter et al. [43] have proposed two CIN: CIN25 and CIN70 (the number 
shows the number of genes considered in the signature) expression signatures that were used 
to predict survival in lung adenocarcinoma, medulloblastoma, breast cancer, lymphoma and 
other tumors. Unfortunately, neither CIN25 nor CIN70 was a good prognostic marker in neu-
roblastoma. Table 1 shows some genes included in the CIN signatures together with genes 
that are involved in the mitotic control and that can contribute to CIN after their deregulation. 
The complexity of CIN is shown by the presence of at least two CIN: the whole chromo-
some instability (W‐CIN) characterized by additional entire chromosome and the segmental 
chromosome instability (S-CIN) that shows chromosome structural changes such as deletion, 
amplification and rearrangements.
In neuroblastoma, we often found W‐CIN in localized stage 1 and 2 tumors, while both W‐CIN 
and S‐CIN are detectable in tumors of stage 3, 4 and 4S. How W‐CIN and S‐CIN can contribute 
to the tumorigenesis is still unclear. A mathematical model [44] indicates that abnormal numeri-
cal whole chromosome number occurs very early in stage 4S (Figure 3). Additional whole chro-
mosome aberration is followed by segmental chromosome damage in stage 4 tumors. So, we can 
argue that W‐CIN is beginning in stage 4S and W‐CIN together with S‐CIN is present in stage 4.
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Gene Locus OMIM Function
ATRX Xq21.1 300032 Associated with pericentromeric heterochromatin during interphase 
and mitosis; ATRX protein is also associated with chromosomes 
during mitosis
AURKA 20q13.2 603072 Induction of centrosome duplication-distribution abnormalities and 
aneuploidy
AURKB 17p13.1 604970 Direct interaction between CENPA and AURKA
BRRN1 2q11.2 602332 Involved in interphase and mitotic condensation
BUB1 2q13 602452 Protects centromeric cohesion during mitosis throughout SGO1
CNAP1 20q11.22 609689 Human rootletin (CROCC) bound CNAP1 at the proximal end of 
centrioles and formed the bridge between two centrioles
CDCA8 1p34.3 609977 CDCA8 interacts with AURKB and survivin (BIRC5)
CDC2 10q21.2 116940 Coordinates spindle assembly with the cell cycle during mitosis 
through phosphorylation of RCC
CDC20 1q34.2 603618 CDC20 together with HCDH1 active APC during mitosis and G1
CCNB1 5q13.2 123836 CCNB1 with p34 (cdc2) (CDK1) form a mitosis‐promoting factor
CENPE 4q24 117143 Associates with kinetochores
ECT2 3q26.31 600586 ECT2 is localized in central spindle at anaphase and promotes local 
activation of RhoA GTPase
ESPL1 12q13.13 604143 Loss of sister chromatid cohesion activity
FOXM1 12p13.33 602341 Regulates expression of cell cycle proteins
H2AFX 11q23.3 601772 Involved in chromatin conformation
MAD2L1 4q27 601467 Induction of chromosome instability by overexpression of the mitotic 
checkpoint gene Mad2
NEK2 1q32.3 604043 Overexpression of active NEK2 induces a splitting of centrosomes
KIF4A Xq13.1 300521 In HeLa cells, KIF4 interacted directly during spindle midzone 
formation
PTTG1 5q33.3 604147 PTTG1 appeared to be an anaphase‐promoting complex
PRC1 15q26.1 603484 In HeLa cells, PRC1 together KIF4 interacted directly during spindle 
midzone formation
TOP2A 17q21.2 126430 Involved in chromosome segregation
TPX2 20q11.21 605917 Involved in microtubule organization during mitosis and normal 
spindle morphology
TTK 6q14.1 604092 Regulator of genetic stability and spindle apparatus
In the Table are listed genes participating in the CIN. The chromosome locus, OMIM code and function are reported for 
each gene. Some genes such as AURKAB, BUB1, CNAP1 and CDCA8 cooperate with other genes in the control of genetics 
stability and mitotic checkpoint (derived from Refs. [43, 45]).
Table 1. Genes involved in CIN.
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As underlined before, Neuroblastic Tumors show biological and morphological heterogeneous 
features. It is possible that genotype‐phenotype aspects reflect diverse road of the genesis of 
this tumor in which different genes are involved with different critical damages. This scenario 
makes the study of neuroblastoma tumorigenesis very complex.
7. Conclusion
Today, we have a huge amount of biological and clinical data of neuroblastoma. We know 
genome mutations and gene expression abnormality occurring in neuroblastoma cells. 
However, all data are referring to the tumor cells at onset of the disease and in same cases 
at relapse. Up to now, we have no information about the tumorigenesis of the tumor. The 
initial phases of tumor growth and progression are very important for the diagnosis and 
treatment of neuroblastoma. Very few mutations are present in this pediatric cancer, and the 
mutational two‐step or multistep models do not completely fitting with the neuroblastoma 
Figure 3. Model of genomic instability in neuroblastoma. The model suggests that tumor of stage 4S and 4 originates 
from NCC by numerical copy number abnormalities (CNAs) for stage 4S and numerical together with structural CNAs 
for stage 4. After infant life, only tumors with high genomic instability either stage 4S or stage 4 develop, contributing 
to disease progression [44].
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tumorigenesis. We develop a mathematical models to explain the genesis of this tumor. 
Moreover, we have several information about the chromosome damage and chromothrip-
sis, suggesting that CIN plays a crucial role in neuroblastoma tumorigenesis. Some animal 
models seem to recapitulate the development of the tumor, focusing our attention to few 
crucial genes. However, we are still in the dark zone and the origin and development of 
neuroblastoma remains unsolved.
Acknowledgements
The work was supported by Italian Neuroblastoma Foundation (Fondazione Italiana per la 
Lotta al Neuroblastoma).
Author details
Gian Paolo Tonini
Address all correspondence to: gp.tonini@irpcds.org
Neuroblastoma Laboratory, Pediatric Research Institute, Città della Speranza, Padua, Italy
References
[1] Esposito MR, Aveic S, Seydel A, Tonini GP. Neuroblastoma treatment in the post‐
genomic era. Journal of Biomedical Science. 2017;24(1):14
[2] Schramm A, Koster J, Assenov Y, Althoff K, Peifer M, Mahlow E, Odersky A, Beisser D, 
Ernst C, Henssen AG, et al. Mutational dynamics between primary and relapse neuro-
blastomas. Nature Genetics. 2015;47(8):872-877
[3] Tonini GP, Nakagawara A, Berthold F. Towards a turning point of neuroblastoma ther-
apy. Cancer Letters. 2012;326:128-134
[4] Haupt R, Garaventa A, Gambini C, Parodi S, Cangemi G, Casale F, Viscardi E, Bianchi M, 
Prete A, Jenkner A, et al. Improved survival of children with neuroblastoma between 1979 
and 2005: A report of the Italian Neuroblastoma Registry. Journal of Clinical Oncology: 
Official Journal of the American Society of Clinical Oncology. 2010;28(14):2331-2338
[5] Nakagawara A, Ohira M. Comprehensive genomics linking between neural develop-
ment and cancer: Neuroblastoma as a model. Cancer Letters. 2004;204(2):213-224
[6] De Preter K, Vandesompele J, Heimann P, Yigit N, Beckman S, Schramm A, Eggert A, 
Stallings RL, Benoit Y, Renard M, et al. Human fetal neuroblast and neuroblastoma tran-
scriptome analysis confirms neuroblast origin and highlights neuroblastoma candidate 
genes. Genome Biology. 2006;7(9):R84
Neuroblastoma - Current State and Recent Updates30
[7] Luksch R, Castellani MR, Collini P, De Bernardi B, Conte M, Gambini C, Gandola L, 
Garaventa A, Biasoni D, Podda M, et al. Neuroblastoma (peripheral neuroblastic tumours). 
Critical Reviews in Oncology/Hematology. 2016;107:163-181
[8] Matthay KK, Maris JM, Schleiermacher G, Nakagawara A, Mackall CL, Diller L, Weiss 
WA. Neuroblastoma. Nature Reviews Disease Primers. 2016;2:16078
[9] Shimada H, Ambros IM, Dehner LP, Hata J, Joshi VV, Roald B, Stram DO, Gerbing RB, 
Lukens JN, Matthay KK, et al. The International Neuroblastoma Pathology Classification 
(the Shimada system). Cancer. 1999;86(2):364-372
[10] Tonini GP. Neuroblastoma: A multiple biological disease. European Journal of Cancer. 
1993;29A(6):802-804
[11] Maris JM, Hogarty MD, Bagatell R, Cohn SL. Neuroblastoma. Lancet. 2007;369:2106-2120
[12] Ikeda Y, Lister J, Bouton JM, Buyukpamukcu M. Congenital neuroblastoma, neuro-
blastoma in situ, and the normal fetal development of the adrenal. Journal of Pediatric 
Surgery. 1981;16(4 Suppl 1):636-644
[13] Gigliotti AR, Di Cataldo A, Sorrentino S, Parodi S, Rizzo A, Buffa P, Granata C, Sementa 
AR, Fagnani AM, Provenzi M, et al. Neuroblastoma in the newborn. A study of the 
Italian Neuroblastoma Registry. European Journal of Cancer. 2009;45(18):3220-3227
[14] Longo L, Panza E, Schena F, Seri M, Devoto M, Romeo G, Bini C, Pappalardo G, Tonini 
GP, Perri P. Genetic predisposition to familial neuroblastoma: Identification of two novel 
genomic regions at 2p and 12p. Human Heredity. 2007;63(3-4):205-211
[15] Mosse YP, Laudenslager M, Longo L, Cole KA, Wood A, Attiyeh EF, Laquaglia MJ, 
Sennett R, Lynch JE, Perri P, et al. Identification of ALK as a major familial neuroblas-
toma predisposition gene. Nature. 2008;455(7215):930-935
[16] Stanton BR, Parada LF. The N‐myc proto‐oncogene: Developmental expression and in 
vivo site‐directed mutagenesis. Brain Pathology. 1992;2(1):71-83
[17] Iwahara T, Fujimoto J, Wen D, Cupples R, Bucay N, Arakawa T, Mori S, Ratzkin B, 
Yamamoto T. Molecular characterization of ALK, a receptor tyrosine kinase expressed 
specifically in the nervous system. Oncogene. 1997;14(4):439-449
[18] Bosse KR, Diskin SJ, Cole KA, Wood AC, Schnepp RW, Norris G, Nguyen le B, 
Jagannathan J, Laquaglia M, Winter C, et al. Common variation at BARD1 results in the 
expression of an oncogenic isoform that influences neuroblastoma susceptibility and 
oncogenicity. Cancer Research. 2012;72(8):2068-2078
[19] Oldridge DA, Wood AC, Weichert‐Leahey N, Crimmins I, Sussman R, Winter C, McDaniel 
LD, Diamond M, Hart LS, Zhu S, et al. Genetic predisposition to neuroblastoma medi-
ated by a LMO1 super‐enhancer polymorphism. Nature. 2015;528(7582):418-421
[20] Schnepp RW, Khurana P, Attiyeh EF, Raman P, Chodosh SE, Oldridge DA, Gagliardi 
ME, Conkrite KL, Asgharzadeh S, Seeger RC, et al. A LIN28B‐RAN‐AURKA signaling 
network promotes neuroblastoma tumorigenesis. Cancer Cell. 2015;28(5):599-609
The Origin of Neuroblastoma
http://dx.doi.org/10.5772/intechopen.69422
31
[21] Schleiermacher G, Michon J, Ribeiro A, Pierron G, Mosseri V, Rubie H, Munzer C, 
Bénard J, Auger N, Combaret V, et al. Segmental chromosomal alterations lead to a 
higher risk of relapse in infants with MYCN‐non‐amplified localised unresectable/dis-
seminated neuroblastoma (a SIOPEN collaborative study). British Journal of Cancer. 
2011;105:1940-1948
[22] Scaruffi P, Coco S, Cifuentes F, Albino D, Nair M, Defferrari R, Mazzocco K, Tonini GP. 
Identification and characterization of DNA imbalances in neuroblastoma by high‐reso-
lution oligonucleotide array comparative genomic hybridization. Cancer Genetics and 
Cytogenetics. 2007;177(1):20-29
[23] Stigliani S, Coco S, Moretti S, Oberthuer A, Fischer M, Theissen J, Gallo F, Garavent 
A, Berthold F, Bonassi S, et al. High genomic instability predicts survival in metastatic 
high‐risk neuroblastoma. Neoplasia. 2012;14:823-832
[24] Tonini GP, Romani M. Genetic and epigenetic alterations in neuroblastoma. Cancer 
Letters. 2003;197(1-2):69-73
[25] Janoueix‐Lerosey I, Schleiermacher G, Michels E, Mosseri V, Ribeiro A, Lequin D, 
Vermeulen J, Couturier J, Peuchmaur M, Valent A, et al. Overall genomic pattern is a 
predictor of outcome in neuroblastoma. Journal of Clinical Oncology: Official Journal of 
the American Society of Clinical Oncology. 2009;27:1026-1033
[26] Schwab M, Alitalo K, Klempnauer KH, Varmus HE, Bishop JM, Gilbert F, Brodeur G, 
Goldstein M, Trent J. Amplified DNA with limited homology to myc cellular oncogene 
is shared by human neuroblastoma cell lines and a neuroblastoma tumour. Nature. 
1983;305(5931):245-248
[27] Brodeur GM, Seeger RC, Schwab M, Varmus HE, Bishop JM. Amplification of N‐myc 
in untreated human neuroblastomas correlates with advanced disease stage. Science. 
1984;224(4653):1121-1124
[28] Oberthuer A, Berthold F, Warnat P, Hero B, Kahlert Y, Spitz R, Ernestus K, Konig R, Haas 
S, Eils R, et al. Customized oligonucleotide microarray gene expression‐based classifica-
tion of neuroblastoma patients outperforms current clinical risk stratification. Journal 
of Clinical Oncology: Official Journal of the American Society of Clinical Oncology. 
2006;24(31):5070-5078
[29] Oberthuer A, Hero B, Berthold F, Juraeva D, Faldum A, Kahlert Y, Asgharzadeh S, Seeger 
R, Scaruffi P, Tonini GP, et al. Prognostic impact of gene expression‐based classifica-
tion for neuroblastoma. Journal of Clinical Oncology: Official Journal of the American 
Society of Clinical Oncology. 2010;28(21):3506-3515
[30] Vermeulen J, De Preter K, Naranjo A, Vercruysse L, Van Roy N, Hellemans J, Swerts 
K, Bravo S, Scaruffi P, Tonini GP, et al. Predicting outcomes for children with neuro-
blastoma using a multigene‐expression signature: A retrospective SIOPEN/COG/GPOH 
study. The Lancet Oncology. 2009;10(7):663-671
[31] Del Grosso F, Coco S, Scaruffi P, Stigliani S, Valdora F, Benelli R, Salvi S, Boccardo 
S, Truini M, Croce M, et al. Role of CXCL13-CXCR5 crosstalk between malignant 
Neuroblastoma - Current State and Recent Updates32
neuroblastoma cells and Schwannian stromal cells in neuroblastic tumors. Molecular 
Cancer Research: MCR. 2011;9(7):815-823
[32] Gross N, Meier R. Chemokines in neuroectodermal cancers: The crucial growth signal 
from the soil. Seminars in Cancer Biology. 2009;19(2):103-110
[33] Pritchard J, Hickman JA. Why does stage 4S neuroblastoma regress spontaneously? 
Lancet. 1994;344(8926):869-870
[34] Knudson AG Jr, Meadows AT. Sounding board. Regression of neuroblastoma IV‐S: A 
genetic hypothesis. The New England Journal of Medicine. 1980;302(22):1254-1256
[35] Lo Cunsolo C, Iolascon A, Cavazzana A, Cusano R, Strigini P, Mazzocco K, Giordani 
L, Massimo L, De Bernardi B, Conte M, et al. Neuroblastoma in two siblings supports 
the role of 1p36 deletion in tumor development. Cancer Genetics and Cytogenetics. 
1999;109(2):126-130
[36] Corallo D, Candiani S, Ori M, Aveic S, Tonini GP. The zebrafish as a model for studying 
neuroblastoma. Cancer Cell International. 2016;16:82
[37] Tonini GP. Neuroblastoma: The result of multistep transformation? Stem Cells. 1993;11 
(4):276-282
[38] Perri P, Longo L, Cusano R, McConville CM, Rees SA, Devoto M, Conte M, Ferrara GB, 
Seri M, Romeo G, et al. Weak linkage at 4p16 to predisposition for human neuroblas-
toma. Oncogene. 2002;21(54):8356-8360
[39] Schleiermacher G, Janoueix‐Lerosey I, Ribeiro A, Klijanienko J, Couturier J, Pierron G, 
Mosseri V, Valent A, Auger N, Plantaz D, et al. Accumulation of segmental alterations 
determines progression in neuroblastoma. Journal of Clinical Oncology: Official Journal 
of the American Society of Clinical Oncology. 2010;28(19):3122-3130
[40] Coco S, Theissen J, Scaruffi P, Stigliani S, Moretti S, Oberthuer A, Valdora F, Fischer M, 
Gallo F, Hero B, et al. Age‐dependent accumulation of genomic aberrations and deregu-
lation of cell cycle and telomerase genes in metastatic neuroblastoma. Journal interna-
tional du cancer [International Journal of Cancer]. 2012;131:1591-1600
[41] Molenaar JJ, Koster J, Zwijnenburg DA, van Sluis P, Valentijn LJ, van der Ploeg I, Hamdi 
M, van Nes J, Westerman BA, van Arkel J, et al. Sequencing of neuroblastoma identifies 
chromothripsis and defects in neuritogenesis genes. Nature. 2012;483(7391):589-593
[42] Tonini GP. Growth, progression and chromosome instability of neuroblastoma: A new 
scenario of tumorigenesis? BMC Cancer. 2017;17(1):20
[43] Carter SL, Eklund AC, Kohane IS, Harris LN, Szallasi Z. A signature of chromosomal 
instability inferred from gene expression profiles predicts clinical outcome in multiple 
human cancers. Nature Genetics. 2006;38(9):1043-1048
[44] Masecchia S, Coco S, Barla A, Verri A, Tonini GP. Genome instability model of meta-
static neuroblastoma tumorigenesis by a dictionary learning algorithm. BMC Medical 
Genomics. 2015;8:57
[45] Schvartzman JM, Sotillo R, Benezra R. Mitotic chromosomal instability and cancer: 
Mouse modelling of the human disease. Nature Reviews Cancer. 2010;10(2):102-115
The Origin of Neuroblastoma
http://dx.doi.org/10.5772/intechopen.69422
33

